Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for February 2012
February 1, 2012
- Mannkind Falls on Stock and Debt Offerings
- Roche Nominates Its Directors to Illumina Board
- Dendreon Announces CEO and Chairman Succession Plan
- Pfizer Announces Voluntary Nationwide Recall Of Lo/Ovral-28 And Norgestrel/Ethinyl Estradiol Tablets Due To Possibility Of Inexact Tablet Counts Or Out Of Sequence Tablets
- UCB and Astellas Announce Agreement to Jointly Develop and Commercialize Cimzia (Certolizumab Pegol) in Japan
- Roche in 2011: Strong results and positive outlook
- Shire and Sangamo Collaborate to Develop Therapeutics for the Treatment of Hemophilia and Other Monogenic Diseases
- Study: E-Prescribing Shown to Improve Outcomes and Save U.S. Healthcare System Billions of Dollars
- D&R Acquires LATHIAN to Create Leading Multichannel Marketing Agency
- Pfizer EVP Among Obama 'Top Money Bundlers'
- Which Pharma company is leading the charge in Productive Innovation for 2012?
- Independent Survey of US Oncologists by National Analysts Worldwide Finds Drug Shortages and Escalating Costs Result in Grave Health Consequences
February 2, 2012
- Agennix AG Halts Phase II/III OASIS Trial in Severe Sepsis
- AstraZeneca?s New Restructuring Initiatives to Drive Productivity and Support Innovation
- Merck Announces Full-Year and Fourth-Quarter 2011 Financial Results
- Novo Nordisk increased operating profit by 18% in 2011
- Are We Sure Our Drugs Are Safe?
- Allergan Reports Fourth Quarter 2011 Operating Results
- Mikulski Bill Would Speed Approval of New Drugs By FDA
February 3, 2012
- Merck KGaA and Threshold Announce Global Agreement to Co-Develop and Commercialize Phase III Hypoxia-Targeted Drug TH-302
- Vertex Posts 4Q Profit on Growing Incivek Sales
- Gilead Sciences 4Q Profit Rises on HIV Drug Sales
- Drug maker Alkermes Fiscal 3Q Loss Widens
- Gilead Sciences Announces Fourth Quarter and Full Year 2011 Financial Results
- Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex, Inc.
- Idenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide Inhibitor, IDX184
- Federal Court Dismisses Whistleblower Lawsuit Against Millennium Laboratories
- Montreal Pharma Research Cluster Threatened Again As AstraZeneca Closes Lab
- Cardinal Health Inc. Seeks Restraining Order to Avoid Disruption in Controlled Medicine Shipments from Florida
February 6, 2012
- Cardinal Health Statement Regarding Temporary Restraining Order to Avoid Disruption in Controlled Medicine Shipments From Florida
- Pharma cos need to compensate clinical trial victims, rules govt
- Merck Provides Update on Development Program for Suvorexant, an Investigational Orexin Receptor Antagonist for the Treatment of Insomnia
- Five Years After HPV Vaccine Law, Virginia Remains Split
- Astellas Pharma Inc.: Reorganization of Astellas?Global Management Structure
- Anacor Pharmaceuticals Announces That Its Partner GSK Has Voluntarily Paused Enrollment of Ongoing GSK ?052 Phase 1 and 2 Clinical Trials
- Cegedim Strategic Data (CSD) Tracks Pharmaceutical Companies' Print Advertising Investments
- Cipher achieves sales milestone for Lipofen
February 7, 2012
- Drug That Prevents Breast Cancer in Some Women Hard on Bones: Study
- Amylin Takes 4Q Loss As Lilly Partnership Ends
- GlaxoSmithKline Shares Edge Lower As Fourth Quarter Figures Prove Slight Disappointment
- Edarbyclor (azilsartan medoxomil and chlorthalidone) Now Available in U.S. Pharmacies for Patients with Hypertension
- GSK Upbeat on Solid Results - Interviews with CEO and CFO
- Illumina's Board Unanimously Rejects Roche's Unsolicited Tender Offer as Inadequate
February 8, 2012
- Sanofi Wins US Approval for Anti-Lice Shampoo
- FDA Will Speed Up Review of Roche Cancer Drug
- Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex
- Roche disappointed by the actions of Illumina, Inc.'s Board of Directors
- Sanofi: 2011 Results Benefit from Genzyme Acquisition
- College Vending Machine Dispenses 'Morning-After' Pill
- GSK Adjusting Its R&D Efforts
- Proton Pump Inhibitors (PPIs) - Drug Safety Communication: Clostridum Difficile-Associated Diarrhea (CDAD) Can be Associated With Stomach Acid Drugs
February 9, 2012
- Impax Laboratories Provides Update on Status of Warning Letter Resolution for its Hayward Facility
- Another Strong Year for Shire With Revenues Exceeding $4 Billion for the First Time and Non GAAP EPS up 26% to $5.34
- Aldagen Sold for More Than $40M
- Alexion Acquires Enobia Pharma For $1.1 Billion
- 'Rx' Is Stylish, Clever Satire of Drug Companies
- Ernst-&-Young-Fined
- Bayer and Almirall to Co-Promote Anticoagulant Rivaroxaban in Spain
- Leo Pharma Sales Reps File Overtime Class Action in New York Federal Court
- India's Global Pharmacy Role Threatened By EU Pact
- SEC Charges Former Pharmaceutical Company Employee with Insider Trading on Biotech Deals
- 2011 Health Spending Growth Remains Near Historic Lows
- Hospira challenges patents on Cubist antibiotic
February 10, 2012
- Mylan CEO Urges Lawmakers to OK Oversight Bill, New Fee
- Pharmaceuticals: Eurozone Owes Firms Euros 12bn
- Osiris Therapeutics Provides Update Regarding the Genzyme/Sanofi Relationship
February 13, 2012
- The Gamida Cell-Teva Joint Venture Concludes Enrollment for the Phase III Study of StemEx, a Cord Blood Stem Cell Product, for Leukemia and Lymphoma
- AmerisourceBergen Announces Departure of Chief Financial Officer Michael DiCandilo; Tim Guttman to Serve as Acting CFO
- Bristol-Myers Squibb Announces Successful Completion of Cash Tender Offer for Shares of Inhibitex, Inc.
February 14, 2012
- Ockham Completes Acquisition of Nexus Oncology
- Karo Bio Terminates the Eprotirome Program
- Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion;
- FDA Seeks $4.5 Billion to Support Medical Product Development, Protect Patients and Ensure Safety of the Food Supply
- Merck Gets FDA OK for Glaucoma Medication
- Lilly Releases Its Most Comprehensive Corporate Responsibility Report
- Hospira Reports Fourth-Quarter and Full-Year 2011 Results
- Biogen Idec to Acquire Stromedix
- Biogen Idec to Acquire Stromedix
- More Changes in Store for Glaxo Than the Move to the Navy Yard
February 15, 2012
- Mylan Actively Addressing Shortage of Preservative-Free Methotrexate Injection
- Teva Reports Fourth Quarter and Full Year 2011 Results
- Avastin (bevacizumab): Counterfeit Product - FDA Issues Letters to 19 Medical Practices
- Roche Warns of Alien Counterfeit Cancer Drug in US
- Roche Warns of Alien Counterfeit Cancer Drug in US
- Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty
- Teva Pharmaceutical 4Q Profit Tumbles 34 Percent
- Reps. Waxman, Markey, DeGette Call on FDA and NIH to Address Failures in Reporting of Clinical Drug Trial Results
- IsZo Capital Writes to Special Committee of Taro Pharmaceutical Demanding the Immediate Rejection of Sun's Buyout Offer
February 16, 2012
- Teva Chief Says Company Prepared in Case of Israel-Iran Conflict
- Biosante Soars Following Drug Approval From FDA
- AstraZeneca Announces First Direct-to-Patient Program Offering the Brand Arimidex (anastrozole) Tablets to Patients for Only $40 Per Month
- Singer Jon Secada Joins Merck and American Liver Foundation's 'Tune In to Hep C' Public Awareness Campaign
- Pfizer Reports Hopeful Signs for Key Drugs
February 17, 2012
- Manufacturers, Market Have Role in Drug Shortages, Sebelius Says
- European Medicines Agency Recommends New Contraindications and Warnings for Aliskiren-Containing Medicines
- US Industry Bickers Over How to Capture Fake Drugs
- Mylan, Pfizer Settle Patent Lawsuit With Two Others
- European Medicines Agency Recommends Lifting Suspension of Aprotinin
- GlaxoSmithKline Receives Positive Opinion in Europe From the CHMP for Nimenrix
- Mylan Resolves Defamation Litigation Against Pittsburgh Post-Gazette and Two of Its Reporters
- Cardinal Health Canada Inc. Announces Expiry of Successful Bid for Futuremed
- Par Pharmaceutical Completes Acquisition of Edict Pharmaceuticals
- Pfizer And Hisun Announce Progress On Potential Joint Venture To Increase Access To High Quality Branded Generic Medicines
February 21, 2012
- GTx Announces Clinical Hold on Clinical Trials Evaluating Capesaris for First and Second Line Treatments of Advanced Prostate Cancer
- Karo Bio Lays Off 16 Employees
- Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year
- Galapagos announces GSK decision to exercise option for investigational medicines GLPG0778 and GLPG0555
- Teva Tempers Laquinimod Prognosis
- Medtronic Allowed to Sell Next-Gen Stent in U.S
- Mylan Inc., Post-Gazette Settle Defamation Lawsuit
- Alex Gorsky to Succeed Bill Weldon as CEO of Johnson & Johnson
February 22, 2012
- Targeting Drug Shortage, Fabry's Patients Sue FDA
- Mylan's Fourth Quarter Net Income Soars
- Johnson & Johnson CEO Steps Down in April, After Consumer Product Recalls
- Supreme Court Will Not Hear J&J Case Over Humira
- UCB Announces Start of C-EARLY Study for Cimzia (Certolizumab Pegol) in Rheumatoid Arthritis
- CEO Bill Weldon to Retire in April at Johnson & Johnson
- FDA Takes Action to Fill Drug Shortages
- Pfizer Statement Regarding CDC's ACIP Discussion of Prevnar 13 for Use in Adults
- Santarus and Depomed Announce Settlement with Lupin of GLUMETZA Patent Litigation
February 23, 2012
- Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. Enter a Collaboration Agreement for XIAFLEX(R) in Canada, Australia, Brazil and Mexico
- Mylan to Launch Generic Copaxone in H2 2013
- FDA Advisory Committee Recommends Approval of Qnexa
- Nuvo Research provides an update on its Pennsaid franchise
- Ranbaxy Crosses $2 Bn in Global Sales
- Vivus Share Price Jumps on Qnexa
February 24, 2012
- Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2011
- Cost of Acquisitions Hurts Endo Pharma 4Q Profit
- Merck Announces Efficiency Program Across All Businesses and Regions
- Spain Moves to Settle Debts to Small Companies
February 27, 2012
- FDA Inquiry Led MU to Shut Down Drug Website
- Alex Gorsky Takes on Consumer Trust.
- New Cancer Drugs 'Axed' to Save Cash
- Remote-Control Drugs May Spell End for Pills, Jabs
- Angiochem Forms Collaboration with GlaxoSmithKline to Discover and Develop Treatments of Lysosomal Storage Diseases
- Pfizer Acquires Alacer Corp., a Leading Vitamin Supplements Company
February 28, 2012
- Purdue Pharma Canada Statement on the Introduction of OxyNEO as a Replacement for OxyContin
- Human Genome Sciences Posts Smaller 4Q Loss
- Forest Laboratories, Inc. and Gedeon Richter Plc. Announce Results from Two Positive Phase III Trials with the Investigational Antipsychotic Cariprazine for the Treatment of Schizophrenia
- Bayer: Sales and EBIT at Record Levels
- ICON Acquires PriceSpective
- Samsung Biologics and Biogen Idec Announce Formation of Biosimilars Joint Venture Samsung Bioepis
- Biogen Idec Submits Application to FDA for Approval of Oral BG-12 to Treat Multiple Sclerosis
- Bayer Maintains Sales Growth in North America
- Quintiles Celebrates 30th Anniversary of Providing Biopharma Solutions
February 29, 2012
- Abbott and Galapagos Announce Global Collaboration for Novel Oral Therapy, GLPG0634, in Phase II to Treat Autoimmune Diseases
- biocrea and Boehringer Ingelheim Conclude Asset Purchase Agreement
- FDA Announces Safety Changes in Labeling for Some Cholesterol-Lowering Drugs
- FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol-lowering Statin Drugs
- Mylan Launches First Equivalent Product to Lexapro Tablets
- FDA Approves Label Changes for Statins
- Sanofi and Astellas to Dissolve Sanofi-Aventis Yamanouchi Pharmaceutical Inc.
- Bristol-Myers Squibb and Duke Translational Medicine Institute Form Strategic Relationship to Broaden Interactions
- Dainippon Sumitomo Pharma Co., Ltd. to Acquire Boston Biomedical Inc. (US Biotechnology Company)
- Alameda County Set to Become First to Force Drugmakers to Take Back Pharmaceuticals
- Merck Provides Information on FDA Post-Marketing Requirement for Sitagliptin
- Monthly Roundup - February 2012
